JAK2 and myeloproliferative neoplasm: In line with the conditions associated with these clonal modifications, the aberrant activation of JAK2 in myeloproliferative neoplasms is associated with the excessive proliferation of myeloid precursor cells, the aberrant release of inflammatory cytokines, and an increase in agglutination and thrombosis (76).